Eidos Therapeutics (NASDAQ:EIDX) issued its quarterly earnings results on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01), MarketWatch Earnings reports.
EIDX opened at $23.51 on Tuesday. Eidos Therapeutics has a fifty-two week low of $8.89 and a fifty-two week high of $24.75.
In other news, CFO Christine Siu sold 11,913 shares of the firm’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $19.66, for a total transaction of $234,209.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
A hedge fund recently raised its stake in Eidos Therapeutics stock. Geode Capital Management LLC lifted its stake in shares of Eidos Therapeutics Inc (NASDAQ:EIDX) by 155.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,021 shares of the company’s stock after acquiring an additional 48,659 shares during the quarter. Geode Capital Management LLC owned 0.22% of Eidos Therapeutics worth $1,101,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 30.15% of the company’s stock.
EIDX has been the subject of a number of research reports. JPMorgan Chase & Co. raised Eidos Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Wednesday, February 27th. BMO Capital Markets initiated coverage on Eidos Therapeutics in a research note on Friday, February 22nd. They set an “outperform” rating and a $28.00 price target for the company. ValuEngine lowered Eidos Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, December 17th. Finally, Zacks Investment Research lowered Eidos Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $27.00.
ILLEGAL ACTIVITY NOTICE: “Eidos Therapeutics (EIDX) Issues Earnings Results” was originally published by Macon Daily and is owned by of Macon Daily. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://macondaily.com/2019/04/16/eidos-therapeutics-eidx-issues-earnings-results.html.
About Eidos Therapeutics
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Featured Story: Cost of equity and a company’s balance sheet
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.